Literature DB >> 8386406

Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients.

C Pouteil-Noble1, R Ecochard, G Landrivon, A Donia-Maged, J C Tardy, S Bosshard, S Colon, H Betuel, M Aymard, J L Touraine.   

Abstract

The study aimed at analyzing the role of CMV infection as a risk factor for rejection occurring after CMV infection because of the clinical consequences of the prevention of CMV infection that might lead to the decrease in rejection episodes. Two hundred forty-two consecutive renal transplant patients were prospectively checked for the occurrence of CMV infection. CMV infection was defined virologically by a positive viremia or/and a positive viruria or/and a seroconversion or/and a significant rise of the anti-CMV antibody titers. Viremia, viruria, and serology were performed weekly for the first month and then at day 90, day 180, and every 6 months, and moreover if clinical symptoms related to a viral infection occurred. Rejection episode was defined by a creatininemia rise of 25%, after cyclosporine nephrotoxicity and urological complications had been discarded, and by the response to the antirejection therapy, steroids, or OKT3 in case of steroid-resistant rejection. The outcome factor was rejection episode occurring from day 4 after the diagnosis of CMV infection. A patient undergoing "a rejection episode after CMV infection" could also be exposed to other potential confounding factors that can be considered as risk factors of rejection among our patients. Rejection occurring before CMV infection was the main factor because it was linked both to CMV infection itself and to "rejection after." Thus infected and noninfected patients were randomly paired off. To the noninfected patient of the pair was attributed the date of a fictitious CMV infection that was the date of the CMV infection of the infected member of the pair. Therefore, "rejection after" and "rejection before" were defined in infected and noninfected patients of the pair according to the time of onset of CMV infection of the infected member of the pair. The incidence of CMV infection was 65%, 157 of the 242 patients were infected, and 85 not infected. Thus 85 pairs of infected-noninfected patients were studied. The incidence of "rejection after" the diagnosis of CMV infection was significantly higher in the group of patients with CMV infection: 45% among infected (38/85) versus 10.60% among noninfected (9/85) (P < 0.0001). Among the 85 pairs, 48 pairs were concordant in which patient of the pair evinced the same outcome factor: 43 showed no rejection after, and 5 showed one.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386406     DOI: 10.1097/00007890-199304000-00032

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  24 in total

Review 1.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

2.  Cytomegalovirus disease in renal transplant recipients: a single-center experience.

Authors:  Dharmendra Bhadauria; R K Sharma; A Kaul; Narayan Prasad; Amit Gupta; Anurag Gupta; Aneesh Srivastava
Journal:  Indian J Microbiol       Date:  2012-04-04       Impact factor: 2.461

Review 3.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 4.  Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.

Authors:  D Ormrod; L J Scott; C M Perry
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138.

Authors:  Siok-Keen Tey; Felicia Goodrum; Rajiv Khanna
Journal:  J Gen Virol       Date:  2010-04-07       Impact factor: 3.891

Review 6.  Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.

Authors:  Javier Bueno; Carmen Ramil; Michael Green
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

7.  Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.

Authors:  R Mañez; S Kusne; M Green; K Abu-Elmagd; W Irish; J Reyes; H Furukawa; A Tzakis; J J Fung; S Todo
Journal:  Transplantation       Date:  1995-04-15       Impact factor: 4.939

8.  Cytomegalovirus infection and unusual early graft dysfunction in a renal transplant recipient.

Authors:  Suzan Sanavi; Ahad Ghods; Reza Afshar
Journal:  J Glob Infect Dis       Date:  2009-01

9.  Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions.

Authors:  Thomas Bachelet; Lionel Couzi; Vincent Pitard; Xavier Sicard; Claire Rigothier; Sébastien Lepreux; Jean-François Moreau; Jean-Luc Taupin; Pierre Merville; Julie Déchanet-Merville
Journal:  J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 10.121

Review 10.  Cytomegalovirus infection in solid organ transplantation: economic implications.

Authors:  Ananya Das
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.